Repligen Corporation (RGEN:NASDAQ) closed at $176.93 on October 23, 2026, down 1.00% on the day. The stock trades 11.0% below its 52-week high of $198.87 and 75.2% above its 52-week low of $100.99. Over the past year, it gained 6.4%. Repligen Corporation is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 23, 2025, RGEN closed higher on 132 days (52%). Its best day was July 28, 2026 (+10.90%) and its worst was April 23, 2026 (-8.31%). The stock moved 10% or more in a single session 1 time.
Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody-based therapeutics, recombinant proteins, and vaccines worldwide. It manufactures various forms of Protein A, a critical component used to purify antibody-based drugs. The company also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields. In addition, it manufactures and sells OPUS pre-packed chromatography columns, which are used in the purification of clinical-stage biologics; and tangential flow filtration cassettes that are used to concentrate clinical and commercial stage biologic drugs. Further, the company has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreich's ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. The comp...
Find more stocks like RGEN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.